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    ABSTRACT          Objectives    The primary objective was to assess the efﬁ  cacy, cycle control and tolerability 
of a monophasic combined oral contraceptive (COC) containing nomegestrol acetate 
(NOMAC) and 17  β  -oestradiol (E2). Effects on acne were evaluated as a secondary objective. 
Results were compared to those of a COC containing drospirenone (DRSP) and 
ethinylestradiol (EE). 
     Methods    Women (aged 18  –  50 years) were randomised to receive NOMAC/E2 
(2.5 mg/1.5 mg) in a 24/4-day regimen (n      1591) or DRSP/EE (3 mg/30   μ  g) in a 21/7-day 
regimen (n        535) for 13 cycles. 
     Results    Estimated Pearl Indices for NOMAC/E2 and DRSP/EE were 0.38 and 0.81 in 
women aged      35 years and 0.31 and 0.66 for all women (18  –  50 years), respectively. Sched-
uled withdrawal bleedings were shorter and lighter among users of NOMAC/E2 and were 
sometimes absent altogether. Intracyclic bleeding/spotting was infrequent in both groups, 
and decreased over time. Type and frequency of adverse events were similar to those typically 
reported for COCs. 
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      INTRODUCTION   
  More than half a century since the ﬁ  rst combined oral 
contraceptive (COC) was introduced, over 100 million 
women use some form of oral contraception  1  . Despite 
its popularity, the Pill is not without side effects  2  , includ-
ing serious risk in rare instances  3  . In order to minimise 
these unwanted effects, COCs have evolved over the 
years with reductions in the dose of the oestrogen com-
ponent  4  , development of different progestogens  5  , and 
modiﬁ  cations in dosing regimens  6  –  8  . While various gen-
erations of progestogens have been developed, ethi-
nylestradiol (EE) has persisted as the oestrogen compo-
nent in nearly all COC formulations, despite direct and 
indirect evidence of its association with thromboembo-
lic complications  9,10  . Early attempts to substitute EE 
with 17  β  -oestradiol (E2) were largely unsuccessful pre-
dominantly due to poor cycle control  10  –  14  . 
  Nomegestrol acetate (NOMAC) combined with E2 
is a monophasic COC containing a selective progesto-
gen structurally similar to progesterone and E2, an 
oestrogen that is identical to the endogenously pro-
duced oestrogen by women during the menstrual cycle. 
NOMAC exhibits strong antigonadotropic activity and 
moderate antiandrogenic properties  15,16  , with no oestro-
genic, androgenic, glucocorticoid, or mineralocorticoid 
activity  15  –  18  . In women, the combination of NOMAC 
and E2 was shown to effectively suppress ovarian func-
tion and thus to inhibit ovulation  19  . 
  In the current study, the contraceptive efﬁ  cacy, cycle 
control, and tolerability of the monophasic 24/4 COC 
containing 2.5 mg NOMAC and 1.5 mg E2 was eval-
uated in comparison to a monophasic (21/7) COC 
containing 3 mg drospirenone (DRSP) and 30   μ  g EE 
in healthy, fertile women.     
    METHODS     
  Study design 
  This was a randomised open-label, comparative multi-
centre trial of the 2.5 mg NOMAC and 1.5 mg 
E2 COC versus a COC containing 3 mg DRSP and 
30   μ  g EE (NCT00511199). Trial participants were 
recruited from gynaecological and/or general prac-
titioner  ’ s practices in Europe, Asia and Australia. 
Doctors were compensated for the costs associated 
with the time and medical care provided to their 
patients, while the participating women did not 
receive ﬁ   nancial compensation other than study 
medicine at no cost and compensation for travelling. 
On average, each of the 95 centres recruited between 
20 and 60 women. Eligible participants who pro-
vided written informed consent were randomly 
allocated in a 3:1 ratio to either NOMAC/E2 or 
DRSP/EE for 13 consecutive cycles of 28 days, 
using an interactive voice-response system. The 
computer-generated randomisation schedule used 
blocks of four and central allocation in the order of 
the randomisation call. Due to the broadened age 
range compared to previous trials with COCs, ran-
domisation was stratiﬁ  ed by age group (18    –    35 years 
and 36    –    50 years). The sample size was based on the 
guidance of the Committee for Medicinal Products 
for Human Use (CHMP) for the precision of the 
Pearl Index estimate of an investigational contracep-
tive drug product  20  . 
  The study was approved by the Independent Ethics 
Committee of each trial centre and it was conducted 
in compliance with current standards and principles of 
the Declaration of Helsinki and the International 
Conference on Harmonisation guidelines for Good 
Clinical Practice.     
  Trial participants 
  Healthy, sexually active women (18    –    50 years) with a 
body mass index between 17 and 35 kg/m  2   who 
needed contraception and did not plan to use con-
doms were included if they met none of the exclusion 
criteria, were willing to provide written informed 
consent, and were willing to participate in the study 
for 13 cycles. The most important exclusion criteria 
   Conclusions    These data show that NOMAC/E2 provides high contraceptive efﬁ  cacy with 
acceptable cycle control as well as an overall adverse event proﬁ  le similar to that of DRSP/EE.   
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and subsequent tablets as scheduled, even if this would 
imply taking two tablets on the same day, or at the same 
time. To maintain contraceptive protection, forgotten 
tablets might require the additional use of condoms 
until seven days of uninterrupted daily tablet intake, but 
this was differently deﬁ   ned for the two treatment 
groups. Subjects on NOMAC/E2 were allowed to miss 
one active tablet at any time, or two tablets between 
days 8 and 17 of a cycle, without the requirement of 
additional condom use; those on DRSP/EE were only 
allowed to miss one active tablet in the second week 
(cycle days 8    –    14), with all other active tablet omissions 
requiring additional use of condoms.     
  Measurements and analyses 
  This large multinational trial was designed     –     in con-
junction with an American twin trial of similar size     –     
to obtain a combined 95% conﬁ  dence interval (CI) 
for the Pearl Index in women      35 years of age, which 
fulﬁ   lled the CHMP criterion such that the upper 
limit of the CI and the point estimate did not exceed 
1 with a probability (power) of at least 80%  20,21  . A 
sample size of one third for the comparator drug was 
considered sufﬁ  cient to investigate the differences in 
cycle control, safety and acceptability. These sample 
size considerations led to 1260 versus 420 subjects for 
the     35 year old population. For the overall popula-
tion (18    –    50 years) a total sample size of 1560 vs. 520 
subjects was planned for NOMAC/E2 and DRSP/
EE, respectively. 
  All randomised subjects who took at least one 
dose of trial medication (All Subjects Treated, or AST 
group) were included in the safety analysis. Contracep-
tive efﬁ   cacy analyses were based on the Intent-
to-Treat (ITT) group, which consisted of all subjects 
from the AST group. 
  Compliance was assessed by counting dispensed 
tablets and unused tablets and by examining the 
patient  ’ s record in the electronic diaries. 
  Participants used electronic diaries on a daily basis 
to record pill intake and to document vaginal bleeding. 
Condom use and vaginal intercourse information was 
to be recorded by the woman at the end of each cycle 
in the electronic diary. 
  Contraceptive efﬁ   cacy analyses using the Pearl 
Index were performed for the ITT group, with the 
exclusion of   ‘  not at risk  ’  cycles, i.e., cycles during 
which condoms were consistently used, as determined 
entailed contraindications for contraceptive steroids; 
an abnormal cervical smear (suggesting dysplasia, cer-
vical intraepithelial neoplasia [CIN], SIL, carcinoma 
in situ, or invasive carcinoma) at screening; a clinically 
relevant abnormal laboratory result at screening as 
judged by the investigator; use of an injectable hor-
monal method of contraception within six months of 
an injection with a three-month duration, within four 
months of an injection with a two-month duration, 
within two months of an injection with a one-month 
duration; or present use or use within two months 
prior to the start of the trial medication of the fol-
lowing drugs: phenytoin, barbiturates, primidone, car-
bamazepine, oxcarbazepine, topiramate, felbamate, 
rifampicin, nelﬁ  navir, ritonavir, griseofulvin, ketocon-
azole, sex steroids (except allowed contraceptive 
methods used before and after the treatment period) 
and herbal remedies containing   Hypericum perforatum   
(St John  ’ s Wort).     
  Treatment 
  From day 1 to day 28, one tablet was to be taken orally 
at approximately the same time daily for 13 consecutive 
28-day cycles. Treatment was either with the investiga-
tional product (24 tablets containing 2.5 mg NOMAC 
and 1.5 mg E2 to be taken on days 1    –    24 and four 
placebo tablets to be taken on days 25    –    28) or the com-
parator (Yasmin  ®  : 21 tablets containing 3.0 mg 
drospirenone and 30   μ  g EE to be taken on days 1    –    21 
and seven placebo tablets to be taken on days 22    –    28). 
Women with no preceding hormonal contraceptive 
use were instructed to begin with the trial medication 
on the ﬁ  rst day of menstrual bleeding (starting on days 
2    –    5 was allowed if a condom was used too during the 
ﬁ   rst seven days of trial medication use). Those 
switching from another hormonal contraceptive (COC, 
vaginal ring, or transdermal patch) started the trial 
medication anytime within seven days after their last 
active tablet (in the case of COC use) or preferably on 
the day of removal, but at the latest when the next 
application would have been due (for users of the vagi-
nal ring or transdermal patch). Women changing from 
a progestogen-only pill or implant, or from a hormonal 
intrauterine system (IUS) were switched immediately 
after discontinuing their previous method. 
  A tablet was considered forgotten when taken more 
than 12 hours late. In such cases subjects were instructed 
to take the last forgotten tablet as soon as remembered Efﬁ  cacy and safety of NOMAC/E2  Mansour et al.
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from the electronic diary data. In the event a woman 
was reported to have become pregnant in a cycle 
deﬁ  ned  as    ‘  not at risk  ’  , the pregnancy would be 
counted, and the cycle would be included in the expo-
sure (denominator of the Pearl Index). Any exposure 
recorded after the estimated date of conception was 
not used in the denominator. 
  Contraceptive efﬁ  cacy was assessed by the occur-
rence of in-treatment pregnancies, i.e., pregnancies 
with a conception date between the day of the ﬁ  rst 
intake of trial medication and the last day of intake 
extended by two days (two-day window). The contra-
ceptive efﬁ   cacy was expressed as the Pearl Index 
(in-treatment pregnancies per 100 woman-years of 
exposure) for the ITT group in subjects        35 years of 
age, with the exclusion of cycles (as determined from 
the electronic diary data) during which condoms were 
consistently used as a barrier back-up method, and with 
a woman-year to equal 13 times a cycle of 28 days 
(      364 days). Additional Pearl Index calculations were 
performed for the overall age class. The 95% CIs for 
the Pearl Index were calculated assuming an underlying 
Poisson distribution  22  . In addition, life-table analyses 
were performed for the ITT Group excluding backup 
cycles. This analysis was based on all subjects from the 
ITT group with at least one cycle without consistent 
use of condoms. In-treatment pregnancies were by 
deﬁ  nition the same as used in the Pearl Index calcula-
tions. Cumulative pregnancy rates after 13 cycles of 
treatment (i.e., at day 364) were calculated using Kaplan 
Meier estimates and 95% CIs, and expressed as rates in 
100 women. Life-table analyses were performed in the 
age class of 18    –    35 years and the overall age class. 
  Pearl Index calculations were also done for several 
subgroups, including age (     24,  25   –    35,      36  years); 
race (White, Asian, Black/African American, Other); 
smoking (yes/no); body weight (     60,  60 –  80,      80 
kg); BMI (     18.5, 18.5 –       25, 25 –       30,     30 kg/m 2  ); 
and starters/switchers. 
  Vaginal bleeding was classiﬁ  ed as spotting (requiring 
none or at most one pad/tampon per day) or bleeding 
(requiring more than one pad/tampon per day). A ref-
erence period (RP) analysis was performed in accor-
dance with World Health Organisation (WHO)  23,24   
and CHMP recommendations. This analysis used a 
ﬁ   xed 91-day reference period as the basis and was 
performed for the ITT Group. Reference periods were 
considered evaluable if no more than two consecutive 
days with missing bleeding information occurred 
within a RP.   There were four RPs: RP1 from day 1 
to day 91; RP2 from day 92 to day 182; RP3 from 
day 183 to day 273; RP4 from day 274 to day 364 
(the theoretical end of the trial). 
  The vaginal bleeding patterns were also analysed by 
a so-called cycle analysis based on the bleeding records 
from the electronic diary. This analysis used evaluable 
cycles as the basis and was performed for the ITT 
group. Cycles were deﬁ  ned as evaluable if they had a 
length of between 22 and 35 days, and no more than 
two consecutive days with missing bleeding informa-
tion. One or two consecutive days with missing bleed-
ing information were interpolated by the bleeding 
information of the preceding day; the interpolation 
rule was therefore the same as in the RP analysis. 
  For subjects in the DRSP/EE group, a 28-day cycle 
consisted of an   ‘  expected non-bleeding period  ’  of 21 
days during active tablet intake followed by a seven-
day  ‘  expected bleeding period  ’  of placebo tablets start-
ing on day 22. Because NOMAC/E2 is given in a 
24/4 regimen, the   ‘  expected bleeding period  ’  was 
adjusted to the same length of seven days in order to 
allow comparisons between the two treatment groups; 
for NOMAC/E2, the   ‘  expected bleeding period  ’  
started on the day of the ﬁ  rst placebo tablet (day 25) 
and ended on day 3 of the next cycle. As a result, the 
  ‘  expected non-bleeding period  ’  in the NOMAC/E2 
group started on day 4 of active pill intake. 
  The two primary vaginal bleeding parameters in the 
cycle analysis were (i) the occurrence of breakthrough 
bleeding/spotting, and (ii) the absence of with-
drawal bleeding. Withdrawal bleeding was classiﬁ  ed as 
any bleeding/spotting episode that began or continued 
into the   ‘  expected bleeding period  ’  . Breakthrough 
bleeding/spotting was classiﬁ  ed as any bleeding/spotting 
episode that occurred during the   ‘  expected non-bleeding 
period  ’  , unless already classified as withdrawal 
bleeding. 
  For both primary bleeding parameters, exact bino-
mial, 2-sided 95% CIs were calculated per treatment 
group and cycle. Treatment groups were compared for 
cycles 2  –  13 using 2-sided 95% CIs (normal approxi-
mation) for the differences between the groups. No 
comparisons were done for cycle 1 due to different 
starting procedures related to pre-trial use of contra-
ceptives. Data on withdrawal bleeding in cycle 13 were 
incomplete and are not presented (e.g., subjects short-
ened the last placebo period, or did not report the 
complete bleeding data for the full length of the Efﬁ  cacy and safety of NOMAC/E2    Mansour et al.
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NOMAC/E2 and DRSP/EE groups, respectively, 
taking the daily tablet on at least 95% of the days 
during the treatment period. A similar compliance 
was calculated on the basis of tablet intake recorded 
in the daily diary; based on non-missing intake data, 
94.9% of NOMAC/E2 users and 91.4% of DRSP/
EE users took the daily tablet on at least 95% of the 
treatment days.     
  Efﬁ  cacy 
  The primary efﬁ  cacy analysis (Table 2) was based on 
in-treatment pregnancies among women      35 years in 
cycles considered at risk of pregnancy (i.e., excluding 
cycles during which condoms were always used). In 
the NOMAC/E2 group four pregnancies occurred 
during 1058 woman-years of exposure and the cor-
responding Pearl Index estimate in women      35 years 
was 0.38 (95% CI 0.10  –  0.97). In one case the preg-
nancy occurred in an apparently treatment-compliant 
woman, without conditions or concomitant drug 
intake that might interfere with contraceptive efﬁ  cacy; 
in the other three cases, circumstances possibly affect-
ing contraceptive efﬁ  cacy were noted, namely, an ear-
lier period of diarrhoea, an earlier bout of severe vom-
iting and one case with suggested, but insufﬁ  ciently 
documented, non-compliance with tablet intake. In 
the DRSP/EE group, three in-treatment pregnancies 
occurred during 372 woman-years of exposure, result-
ing in a Pearl Index of 0.81 (95% CI 0.17  –  2.35) in 
women     35 years. In one case, non-compliance with 
tablet intake was conﬁ  rmed, in the other two cases, 
non-compliance was suspected but insufﬁ  ciently doc-
umented. Overall, in the same age group, 3.1% of the 
cycles on NOMAC/E2 and DRSP/EE were affected 
by documented insufﬁ   cient compliance, i.e., use of 
prohibited concomitant medication, missing more 
than four active tablets in a cycle, or more than two 
active tablets in a row. For users      35 years old, results 
from the subgroup analysis suggested that the contra-
ceptive efﬁ  cacy of NOMAC/E2 was independent of 
the demographics and subgroups analysed (age, race, 
smoking status, weight and BMI; results not shown). 
In the age group 36  –  50 years no pregnancies occurred. 
Life-table analyses were consistent with the Pearl 
Index estimates, with cumulative one-year pregnancy 
rates in women      35 years of 0.40 (95% CI 0.15  –  1.06) 
and 0.77 (95% CI 0.25  –  2.39) for NOMAC/E2 and 
DRSP/EE, respectively (Table 2). 
  ‘  expected bleeding period  ’  at the end of cycle 13 and 
the beginning of the subsequent follow-up cycle). 
  Secondary vaginal bleeding parameters in the cycle 
analysis included: the occurrence of breakthrough 
bleeding, the occurrence of breakthrough spotting 
(spotting only), the number of breakthrough bleeding/
spotting days, and the number of withdrawal bleeding/
spotting days. 
  The effects on acne were also evaluated, as a second-
ary objective. Regular skin examinations were carried 
out during the trial in order to explore the effect of 
both COCs on acne. Acne was examined by the study 
staff at screening and at all visits after randomisation 
and they were asked to score acne as being   ‘  none  ’  , 
  ‘  mild  ’  ,   ‘  moderate  ’  or   ‘  severe  ’  according to their own 
judgment. The study staff recorded any increase in 
severity of acne from baseline on the adverse events’ 
(AEs) form. 
  Safety data were obtained by monitoring of (seri-
ous) AEs, routine laboratory parameters, vital signs 
and cervical smear, and by performing physical and 
gynaecological examinations. 
  All statistical analyses were done using SAS statistical 
software for Windows (SAS Institute, Cary, NC, 
USA).       
    RESULTS     
  Subjects 
  Out of a total of 2152 women, 1613 were randomised 
to NOMAC/E2 and 539 to DRSP/EE. Of the 2152 
randomised women, 2126 were treated and 1552 
completed the trial. In the NOMAC/E2 group, 22 
subjects were not treated due to withdrawal of con-
sent (  n        5), pregnancy (  n        8), and other personal 
reasons (  n       9). Of 1591 treated women, 449 (28.2%) 
discontinued prematurely. In the DRSP/EE group, 
four subjects were not treated due to withdrawal of 
consent (  n       1), pregnancy (  n       1) and other personal 
reasons (  n        2). Out of 535 women treated, 125 
(23.4%) discontinued prematurely (Figure 1). Demo-
graphic characteristics of participants were similar in 
both groups (Table 1).     
  Compliance 
  Based on data of returned tablets, compliance was 
high, with 94.8% and 91.4% of women in the Efﬁ  cacy and safety of NOMAC/E2  Mansour et al.
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  Thus, the pregnancy rates for NOMAC/E2 were 
consistently lower than those for DRSP/EE, but the 
differences between the treatment groups were not 
statistically signiﬁ  cant.     
  Vaginal bleeding 
  The data of the RP analysis showed a lower mean 
number of bleeding/spotting days in the NOMAC/
E2 group compared with the DRSP/EE group across 
the reference periods (Figure 2). For NOMAC/E2 
the number of bleeding-spotting days per reference 
period declined from 14.9 during RP1 to 10.6 during 
RP4, while for DRSP/EE the numbers remained the 
same over time, i.e., 18.5 (RP1) and 19.2 (RP4). The 
difference between the two treatments increased with 
time to about 8.6 days per reference period at RP4, 
and was largely caused by an excess of bleeding days 
with DRSP/EE as compared to NOMAC/E2 (12.4 
vs. 4.4 days in RP4). According to the deﬁ  nitions of 
the reference period analysis, the incidence of amen-
orrhoea, i.e., no bleeding-spotting at all over a 
consecutive period of 91 days, increased from 8.1% 
in RP2 to 13.4% in RP4 for NOMAC/E2 users; 
amenorrhoea was almost absent among users of 
DRSP/EE (1.1% in RP4). 
  In the cycle analysis breakthrough bleeding/spotting 
was found to progressively decrease in both groups over 
the course of the trial. The respective incidences for 
NOMAC/E2 and DRSP/EE (Cycles 4  –  13) were simi-
lar and ranged from 20% to 14% and from 17% to 11%, 
respectively, and occasionally reached statistical signiﬁ  -
cance between treatments (Figure 3A).      For women 
with breakthrough bleeding/spotting, the median num-
ber of days per cycle was similar between treatment 
arms (2  –  3 days in the NOMAC/E2 group and 1  –  4 days 
in the DRSP/EE group) (Figure 3B). In both treatment 
groups, the majority (      75%) of breakthrough bleed-
ing/spotting episodes consisted of spotting only. 
  Scheduled withdrawal bleedings were shorter and 
lighter among users of NOMAC/E2, and were some-
times absent altogether. A progressive increase in the 
incidence of absence of withdrawal bleeding was 
observed in the NOMAC/E2 group, ranging from 
22% (Cycle 4) to 31% (Cycle 12), which was 
not observed in the DRSP/EE group (varying 
between 3 and 6% without particular trend). The dif-
ference between the treatment groups was statistically 
      Figure 1   Patient ﬂ  ow through the trial. NOMAC, nomegestrol acetate; E2, oestradiol; EE, ethinylestradiol; DRSP , drospirenone; 
AE, adverse event.   Efﬁ  cacy and safety of NOMAC/E2    Mansour et al.
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on the subgroup of women who had missed their 
withdrawal bleeding in at least one of the cycles 2, 3 
or 4. This subgroup comprised 30% of the women 
enrolled on NOMAC/E2 and the incidence of absence 
of withdrawal bleeding during later cycles (cycles 
5-13) ranged between 53% and 66%. This increased 
tendency for absent withdrawal bleeding was also 
noted in the similarly deﬁ  ned subgroup of the DRSP/
EE group, although the number of women qualifying 
for the subgroup was too low to generalise results. The 
incidence of breakthrough bleeding-spotting during 
cycles 5  –  13 among women who experienced absence 
of withdrawal bleeding during any of the cycles 2, 3 
or 4 ranged between 11% and 23%, and was compa-
rable to the overall group incidence (14  –  21%); absence 
signiﬁ   cant for all cycles (Figure 4A). For women 
experiencing withdrawal bleeding, the median num-
ber of withdrawal bleeding/spotting days was lower 
when using NOMAC/E2 (range 3  –  4 days) compared 
to DRSP/EE (5 days) (Figure 4B), the difference 
being caused by the median number of bleeding days, 
i.e., two days for NOMAC/E2 and three days for 
DRSP/EE. Calculated over the entire trial period for 
all NOMAC/E2 users and based on evaluable cycles, 
43% of women on NOMAC/E2 never missed a 
withdrawal bleeding, while another 21% missed 
exactly one, and another 9% missed two withdrawal 
bleedings. 
  To investigate the predictability of absence of with-
drawal bleeding, additional analyses were performed 
      Table 1   Demographic characteristics of subjects at screening.   
  NOMAC/E2   DRSP/EE   Total 
  N 1591 535 2126
  Age 
Mean years (SD) 28 (7) 28 (7) 28 (7)
18  –  35 years   n   (%) 1319 (82.9%) 443 (82.8%) 1762 (82.9%)
36  –  50 years   n   (%) 272 (17 .1%) 92 (17 .2%) 364 (17 .1%)
  Race     n   (%)
Asian 77 (4.8%) 26 (4.9%) 103 (4.8%)
Black/African American 4 (0.3%) 3 (0.6%) 7 (0.3%)
White/Caucasian 1501 (94.3%) 501 (93.6%) 2002 (94.2%)
Other 9 (0.6%) 5 (0.9%) 14 (0.7%)
  Ethnicity     n   (%)14
Missing 1 0 1
Hispanic or Latino 15 (0.9%) 8 (1.5%) 23 (1.1%)
Not Hispanic or Latino 1575 (99.1%) 527 (98.5%) 2102 (98.9%)
Body weight, mean kg (SD) 63.4 (10.5) 63.7 (10.1) 63.5 (10.4)
BMI, mean kg/m  2   (SD) 23.0 (3.5) 23.0 (3.4) 23.0 (3.5)
Smoking   n   (%) 381 (24.0%) 146 (27 .3%) 527 (24.8%)
Contraceptive method at screening   n   (%)
None 155 (9.7%) 58 (10.8%) 213 (10.0%)
COC
All 1072 (67 .4%) 356 (66.5%) 1428 (67 .2%)
DRSP/EE only 281 (17 .7%) 73 (13.6%) 354 (16.7%)
Foam, condom, suppositories,     diaphragm 255 (16.0%) 83 (15.5%) 338 (15.9%)
POP 34 (2.1%) 16 (3.0%) 50 (2.4%)
Hormonal IUD 10 (0.6%) 5 (0.9%) 15 (0.7%)
Non-hormonal IUD 14 (0.9%) 6 (1.1%) 20 (0.9%)
NuvaRing    ®   28 (1.8%) 5 (0.9%) 33 (1.6%)
Patch 6 (0.4%) 4 (0.7%) 10 (0.5%)
      NOMAC/E2, nomegestrol acetate/17  β  -oestradiol (NOMAC/E2); DRSP/EE, drospirenone/ethinylestradiol (DRSP/EE); 
BMI, body mass index; COC, combined oral contraceptive; POP , progestogen-only pill; IUD, intrauterine device; POP , 
progestogen-only pill; SD, standard deviation.     Efﬁ  cacy and safety of NOMAC/E2  Mansour et al.
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of withdrawal bleeding in a given cycle was not associ-
ated with the occurrence of breakthrough bleeding-
spotting in the next cycle, nor was the occurrence 
of breakthrough bleeding-spotting in a given cycle 
correlated with absence of withdrawal bleeding in the 
subsequent expected bleeding period.     
  Acne 
  Acne was actively assessed by the study staff at screening 
and at all visits after randomisation. At baseline, acne was 
present in 32.7% and 32.5% of women assigned to the 
NOMAC/E2 and DRSP/EE group, respectively. Over-
all, the presence of acne compared to baseline decreased 
over time with both treatments (Figure 5A). With 
respect to individual changes (Figure 5B), the majority 
of women (  ∼  75%) in both groups showed no change 
in acne status at last measurement. For NOMAC/E2 
and DRSP/EE, respectively, improvement was observed 
in 15.9% and 20.1% of participants, and worsening or 
development of new acne were observed in a smaller 
group of 9.9% and 4.0%, respectively. Of those present-
ing with acne at baseline   –   approximately one third of 
all women   –   improvement was noted in 48.4% 
(NOMAC/E2) and 61.4% (DRSP/EE) of women, 
while worsening was judged to have occurred in 7.2% 
and 1.8% of the NOMAC/E2 and DRSP/EE subjects, 
respectively. Of the women presenting without acne at 
baseline, the vast majority remained free of acne; in 
11.1% (NOMAC/E2) and 5.1% (DRSP/EE) of the 
women, newly developed acne was observed at last 
measurement.     
      Table 2   Summary of contraceptive efﬁ  cacy (Pearl Index and life-table analysis) for nomegestrol acetate/17  β  -oestradiol 
(NOMAC/E2) and drospirenone/ethinylestradiol (DRSP/EE) in the overall population and age subgroups    .
   NOMAC/E2     DRSP/EE 
  18  –  50 years         35        years   18  –  50 years         35     years 
  N 1587 1315 534 442
  Pearl Index analysis 
Exposure (woman-years) 1292.5 1057 .6 452.8 372.4
Pregnancies    *  44 3 3
Pearl Index estimate 0.31 0.38 0.66 0.81
95% CI 0.08, 0.79 0.10, 0.97 0.14, 1.94 0.17 , 2.35
  Life-table analysis 
Cumulative pregnancy rate after 1 year (%) 0.33 0.40 0.64 0.77
95% CI 0.12, 0.87 0.15, 1.06 0.21, 1.97 0.25, 2.39
      CI, conﬁ  dence interval.     
      *   Pregnancies with conception date from the day of ﬁ  rst intake of trial medication up to and including the days of last 
intake of trial medication extended with a maximum of two days. This Pearl Index was calculated by excluding cycles 
with condom use from the analysis.     
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noted in the discontinuation rates due to AEs (Figure 
1), with respective discontinuation rates for NOMAC/
E2 and DRSP/EE of 3.3% vs. 0.2% for acne, 4.0% vs. 
0.7% for irregular (withdrawal) bleeding, and 1.4% vs. 
0.7% for weight increase. Discontinuation owing to 
irregular bleeding did not occur early in the trial, but 
rather gradually over time in the NOMAC/E2 group. 
Serious AEs were reported for 2% of subjects, which 
were evenly distributed between the two treatment 
groups. Three SAEs were deemed as (possibly) treat-
ment-related by the investigators, one in the NOMAC/
E2 group (  ‘  severe menorrhagia  ’  ) and two in the 
DRSP/EE group (  ‘  deep vein thrombosis left calf  ’  and 
  Safety and tolerability 
  Approximately 80% of all participants reported one or 
more AE during the in-treatment period. In the 
NOMAC/E2 and DRSP/EE groups, 51.2% and 
37.0% of the women, respectively had AEs that were 
determined by the investigator to be treatment-related. 
The most frequently reported treatment-related AEs 
(related incidence       5%)  were   ‘  acne  ’  (15.3% for 
NOMAC/E2 vs. 7.1% for DRSP/EE);   ‘  withdrawal 
bleeding irregular  ’  (11.7% vs. 0.4%);   ‘  weight increased  ’  
(7.9% vs. 6.2%); and   ‘  headache  ’  (6.6% vs. 6.2%). Three 
of these AEs accounted for most of the difference 
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Figure 3 (A) Incidences (%) and (B) duration (median number of days) of breakthrough bleeding-spotting for NOMAC/E2 
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  ‘  systemic lupus erythematosus with concomitant patel-
lar tendon bearing  ’  ). 
  Routine laboratory and blood pressure measure-
ments showed no remarkable changes in mean or 
median values from baseline in either treatment group. 
Women on NOMAC/E2 experienced a small increase 
in mean body weight, i.e., from 63.4 kg at baseline to 
64.4 kg at last measurement; women on DRSP/EE 
increased from 63.7 kg at baseline to 64.0 kg at last 
measurement. The change from baseline in weight at 
last measurement was statistically signiﬁ  cant between 
NOMAC/E2 and DRSP/EE (  p       0.001).      
    DISCUSSION   
  Results of this study show that the new monophasic 
COC containing the progesterone-derived progestogen 
NOMAC in combination with the natural oestrogen 
E2 provides robust contraceptive efﬁ  cacy, acceptable 
cycle control, and shorter, lighter periods. This new 
24/4 regimen COC was well tolerated with a safety 
proﬁ  le similar to that of DRSP/EE. 
  Contraceptive efﬁ  cacy as expressed via the estimated 
Pearl Indices (95% CI) for women      35 years were 0.38 
(0.10  –  0.97) for NOMAC/E2 and 0.81 (0.17  –  2.35) for 
DRSP/EE. These values represent the ﬁ  rst estimation 
of the contraceptive efﬁ  cacy for NOMAC/E2. The val-
ues determined for DRSP/EE are similar to those pre-
viously reported for this COC in a European study 
population  25  . For NOMAC/E2 users, the contraceptive 
efﬁ  cacy appeared to be independent of the demograph-
ics (age, race, smoking status, weight and BMI), indicat-
ing the strong contraceptive efﬁ  cacy of NOMAC/E2. 
Moreover, the contraceptive efﬁ   cacy in the present 
study was achieved despite applying less stringent bar-
rier method (condom) back-up contraception require-
ments in users of NOMAC/E2 when tablets had been 
missed. NOMAC/E2 users were allowed to miss one 
active tablet any time and two active tablets mid-cycle 
(Day 8  –  17) without back-up requirement, while for 
DRSP/EE users, one missed active tablet during the 
ﬁ  rst or third week, or two or more active tablets at any 
time, required the use of back-up contraception. This 
high contraceptive efﬁ  cacy of NOMAC/E2 is consis-
tent with the profound ovarian suppression observed 
with NOMAC/E2  19  . The shorter hormone-free inter-
val  26  –  28   of four versus seven days for the DRSP/EE 
COC, combined with the longer terminal elimination 
half-life of NOMAC  18,29,30   compared to DRSP may 
also have contributed to the numerically lower Pearl 
Index values in the NOMAC/E2 group, as observed in 
this study. 
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  The incidences of unscheduled bleeding/spotting 
observed in this trial for DRSP/EE were higher than 
observed in trials reported previously. In one study, 
unscheduled bleeding after cycle 6 was reported at 
8.8%  32  , and in another study, an incidence of 5.4% was 
reported  34  . A possible explanation for the observed 
higher incidence of unscheduled bleeding/spotting is 
the use of the more accurate electronic diaries in the 
current study instead of paper diary cards or a woman  ’ s 
personal recollection during clinic visits  32,34,35  . In the 
current study, women could only enter the daily bleed-
ing information retrospectively for the previous two 
days, providing very accurate values for the incidence of 
unscheduled bleeding/spotting, likely resulting in the 
higher incidences for DRSP/EE users than observed 
with paper diaries. In addition, slight differences in deﬁ  -
nitions and analytical methods might have contributed 
to the observed differences between contraceptives. 
Indeed, this issue was recently addressed by Mishell and 
coworkers  36,37  , who proposed standardised methods for 
data collection and analysis of vaginal bleeding pattern. 
  NOMAC/E2 exhibits a neutral to slightly positive 
effect on acne, which is consistent with its moderate 
effect on sex hormone-binding globulin (SHBG) and 
androgen levels  19  . DRSP/EE has been observed to 
show some efﬁ  cacy in the treatment of mild-to-mod-
erate acne vulgaris  36  –  39  , which may be related to the 
stronger induction of SHBG and more profound 
reduction of androgen production associated with the 
administration of 30 μg EE  19  . The more frequently 
reported acne as an AE can be largely explained by 
the trial methodology as the condition was assessed at 
each clinic visit and study doctors were obliged to 
report any worsening as an AE. This procedure deviates 
from the spontaneous, unsolicited way of AE reporting 
usually applied in clinical trials. Moreover, the frequent 
assessments may also have caused increased awareness 
of acne with both patients and doctors, which in itself 
has the potential to increase reporting rates. 
  Subjects on NOMAC/E2 experienced a 1.00 kg 
increase in mean body weight, compared to 0.35 kg 
for users of DRSP/EE. From placebo-controlled 
studies in typical contraceptive user populations it 
appears that women aged 18  –  35 years, who do not 
use hormonal contraception, gain on average 0.6  –  0.8 
kg of body weight over a period of 6  –  9 months  40  –  42  , 
which is close to the change reported here for 
NOMAC/E2 over a period of one year. Indeed a 
recent extensive overview of the available clinical 
  NOMAC/E2 is associated with a vaginal bleeding 
pattern characterised by shorter and lighter bleeding 
episodes as compared to DRSP/EE. The total number 
of bleeding-spotting days over 91-day reference peri-
ods declined for NOMAC/E2 users over Reference 
Period 1 to 4 from 14.9 to 10.6; for DRSP/EE users 
the respective numbers were 18.5 and 19.2, the excess 
being due to bleeding days. 
  While the incidence and length of breakthrough 
bleeding-spotting episodes were largely comparable 
between the treatment groups, absence of withdrawal 
bleeding was greater in NOMAC/E2 users (22  –  31% 
of NOMAC/E2 users experienced absence of with-
drawal bleeding during Cycles 4  –  12). For NOMAC/
E2 users who had a withdrawal bleed, it was in com-
parison to DRSP/EE of shorter duration (3  –  4 days 
vs. 5 days) and of lighter intensity (2 vs. 3 bleeding 
days). Missed withdrawal bleeding may be an inherent 
feature of the shorter hormone-free period  7,31,32  . 
Missed withdrawal bleedings with NOMAC/E2 may 
be reinforced by the particularly long elimination 
half-life of NOMAC  18,29,30  . Although absence of 
withdrawal bleeding has become widely accepted  33  , it 
was not anticipated at the start of the current trial. 
Consequently, doctors and women were not coun-
selled beforehand on this aspect and this may have 
contributed to a somewhat lower acceptance of the 
bleeding pattern (as reﬂ  ected in the AE and discon-
tinuation data), particularly in view of fear of unin-
tended pregnancy. In fact the latter should not be of 
concern given the extent of ovarian suppression  19   
combined with the NOMAC/E2 contraceptive efﬁ  -
cacy data from this study. Adequate counselling on the 
relative paucity of vaginal bleeding and the high con-
traceptive efﬁ  cacy will likely result in user satisfaction 
with NOMAC/E2. 
  From the data it also appears that NOMAC/E2 
prevents intracyclic bleeding as effectively as the 
DRSP/EE comparator, which contains 30   μ  g EE. This 
is a remarkable observation in view of the initial results 
with COCs containing E2, which showed inadequate 
cycle control that prevented their successful develop-
ment for contraception  25  . It has been postulated that 
in comparison to the progestogens used previously, 
NOMAC is better able to maintain endometrial stabil-
ity in combination with E2, due to its low impact on 
endometrial oestradiol metabolism, allowing the main-
tenance of adequate endometrial E2 concentrations 
and thus preventing endometrial breakdown  29  . Efﬁ  cacy and safety of NOMAC/E2  Mansour et al.
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data has not found a causal relationship between hor-
monal contraceptives and body weight  43  . The increase 
of 0.35 kg reported for DRSP/EE over one year 
of treatment could be explained by the antimi-
neralocorticoid action of DRSP, which results in 
some loss of body water in the ﬁ   rst months of 
treatment  38,44,45  . 
  NOMAC/E2 was well tolerated and showed an AE 
proﬁ   le largely similar to the comparator DRSP/EE, 
except for the reporting of acne, irregular withdrawal 
bleeding and body weight gain, and discontinuation 
related to these conditions. As discussed above, the inci-
dences of these events may have been inﬂ  uenced by the 
frequently scheduled active assessments of acne, body 
weight and bleeding pattern, and the trial methodology 
related to AE capture. Differences between the groups 
may reﬂ  ect differences in the pharmacological proper-
ties of the hormones as well as regimen, while the open-
label design of the trial may have had some effect con-
sidering that DRSP/EE (3 mg/30  μ  g) is a well-established 
COC with a known positive effect on both acne and 
weight gain. While DRSP/EE shows some additional 
pharmacological effects on acne and body weight, 
NOMAC/E2 seems neutral, namely, it appears to have 
no effect on body weight and it is not a cure for acne. 
A similar neutral effect of NOMAC/E2 has been 
observed with respect to parameters of haemostasis, lipid 
metabolism, carbohydrate metabolism, carrier proteins, 
and surrogate markers of adrenal and thyroid function 46,47  . 
However, long-term clinical studies with the appropri-
ate clinical endpoints will be required to assess the clini-
cal relevance of these observations. 
  Overall, the 24/4 monophasic regimen of NOMAC/
E2 showed strong contraceptive efﬁ  cacy and an accept-
able cycle control with short and light withdrawal 
bleeding when administered for 13 cycles in over 1500 
women. NOMAC/E2 was well tolerated and showed 
a safety proﬁ  le that was similar to DRSP/EE. 
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